Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 3/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | NAT1 | P18440 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23036942 | 0.82 | MTOR (0.59) | MTORIGF1RPARP1PTGS2PIM1 | |
| SCHEMBL13345210 | 0.81 | PLK1 (0.65) | MTORPTGS2PTGES | |
| SCHEMBL3391167 | 0.78 | PTGES (0.53) | MTORIGF1RPARP1PTGS2PTGES | |
| SCHEMBL3391172 | 0.78 | PTGES (0.53) | MTORIGF1RPARP1PTGS2PTGES | |
| SCHEMBL3391203 | 0.76 | PTGES (0.54) | MTORPARP1PTGS2PTGES | |
| SCHEMBL3391207 | 0.76 | PTGES (0.54) | MTORPARP1PTGS2PTGES | |
| SCHEMBL4854031 | 0.76 | MEN1 (0.60) | PTGS2TTR | |
| SCHEMBL4854035 | 0.76 | MEN1 (0.60) | PTGS2TTR | |
| SCHEMBL14304515 | 0.74 | PTGS2 (0.58) | PTGS2 | |
| SCHEMBL23036944 | 0.73 | MTOR (0.79) | MTORIGF1RPTGS2PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861395-B1 | 5-(1,3-DIARYL-1H-PYRAZOL-4-YLMETHYLENE)-THIAZOLIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTICANCER AGENT | KOREA RES INST CHEM TECH (KR) | 2010-12-29 | — | — | EP | disclosed |
| US-7718681-B2 | 5-(1,3-Diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine,2,4-dione derivatives useful as anticancer agent | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-05-18 | — | — | US | disclosed |
| US-20080275094-A1 | 5-(1,3-Diaryl-1H-Pyrazol-4-1 Methylene)-Thiazolidine-2,4-Dione Derivatives Useful as Anticancer Agent | BARCLAYS BANK PLC (GB) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275094-A1 | 5-(1,3-Diaryl-1H-Pyrazol-4-1 Methylene)-Thiazolidine-2,4-Dione Derivatives Useful as Anticancer Agent | TP53, CDKN1A, API5 | MTOR 656/4885IGF1R 904/4885PARP1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.